Maraviroc

Generic Name: Maraviroc

Brand Names: Celsentri, Selzentry

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₄₁F_₂N_₅O

CAS Number: 376348-65-1

Unique Ingredient Identifier: MD6P741W8A

Background: Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007.

Indication: Maraviroc is indicated in combination with other antiretroviral agents for the treatment of CCR5-tropic HIV-1 infection in adults and pediatric patients weighing at least 2kg. It is not recommended in patients with dual/mixed- or CXCR4-tropic HIV-1.

Associated Conditions: CCR5-tropic Human Immunodeficiency Virus Type 1 (HIV-1) Infection, Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Clinical Trials

Safety and Efficacy of Maraviroc and/or Favipiravir With Standard Therapy in Severe COVID-19 Adults

Phase 2

Terminated

Conditions: COVID-19

Interventions: Procedure: Curently used therapy for COVID-19 non-critical patients
Drug: Favipiravir + Currently used therapy
Drug: Maraviroc+Favipiravir+CT
Drug: Maraviroc + Currently used therapy

First Posted Date: 2020-07-17

Last Posted Date: 2022-06-03

Lead Sponsor: Hospital General de México Dr. Eduardo Liceaga

Target Recruit Count: 19

Registration Number: NCT04475991

Locations: 🇲🇽
Hospital General de México "Dr. Eduardo Liceaga", Mexico City, Cdmx, Mexico

Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19).

Phase 2

Terminated

Conditions: COVID-19

Interventions: Drug: Maraviroc 300 mg
Other: Standard care therapy

First Posted Date: 2020-06-22

Last Posted Date: 2022-03-11

Lead Sponsor: Hospital Universitario Infanta Leonor

Target Recruit Count: 60

Registration Number: NCT04441385

Locations: 🇪🇸
Hospital Universitario Infanta Leonor, Madrid, Spain
🇪🇸
Hospital Clínic, Barcelona, Spain

Maraviroc in Patients With Moderate and Severe COVID-19

Phase 1

Completed

Conditions: COVID

Interventions: Drug: Maraviroc

First Posted Date: 2020-06-17

Last Posted Date: 2024-04-29

Lead Sponsor: Rhode Island Hospital

Target Recruit Count: 9

Registration Number: NCT04435522

Locations: 🇺🇸
Rhode Island Hospital, Providence, Rhode Island, United States

Pharmacokinetics of Maraviroc and Boosted Atazanavir Dual Regimen in Stable HIV-infected Patients

Phase 3

Withdrawn

Conditions: HIV Infection

Interventions: Drug: maraviroc (300 mg QD) + atazanavir/ritonavir (300 and 200 mg /100 mg QD)

First Posted Date: 2018-10-17

Last Posted Date: 2020-11-06

Lead Sponsor: University of Turin, Italy

Registration Number: NCT03708861

Locations: 🇮🇹
University of Torino, Torino, Italy

Efficacy of Maraviroc in Modulating Atherosclerosis in HIV Patients.

Phase 4

Completed

Conditions: Cardiovascular Risk Factor
HIV Infection With Other Conditions
Atherosclerosis
Inflammation

Interventions: Drug: Maraviroc 300 mg

First Posted Date: 2018-01-18

Last Posted Date: 2018-01-23

Lead Sponsor: University Of Perugia

Target Recruit Count: 22

Registration Number: NCT03402815

Locations: 🇮🇹
Elisabetta Schiaroli, Perugia, Italy

Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC

Phase 1

Completed

Conditions: Metastatic Colorectal Cancer
MSS

Interventions: Biological: Pembrolizumab
Drug: Maraviroc

First Posted Date: 2017-09-07

Last Posted Date: 2022-06-07

Lead Sponsor: University Hospital Heidelberg

Target Recruit Count: 20

Registration Number: NCT03274804

Locations: 🇩🇪
National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany

ENLIGHTEN: Establishing Novel Antiretroviral (ARV) Imaging for Hair to Elucidate Non-Adherence

Phase 4

Completed

Conditions: HIV/AIDS

Interventions: Drug: Dolutegravir Pill
Drug: Truvada Pill
Drug: Maraviroc Pill

First Posted Date: 2017-07-14

Last Posted Date: 2019-11-22

Lead Sponsor: University of North Carolina, Chapel Hill

Target Recruit Count: 36

Registration Number: NCT03218592

Locations: 🇺🇸
Clinical and Translational Research Center, UNC Hospitals, Chapel Hill, North Carolina, United States

Effects of Maraviroc vs. Efavirenz on CD4/CD8 Ratio

Phase 3

Completed

Conditions: HIV/AIDS

Interventions: Drug: Efavirenz QD + Zidovudine/Lamivudine BID
Drug: Maraviroc (UK-427,857) BID + Zidovudine/Lamivudine QD
Drug: Maraviroc (UK-427,857) QD + Zidovudine/Lamivudine BID

First Posted Date: 2017-06-06

Last Posted Date: 2023-09-13

Lead Sponsor: Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

Target Recruit Count: 721

Registration Number: NCT03178084

Maraviroc to Augment Rehabilitation Outcomes After Stroke

Phase 2

Terminated

Conditions: Stroke

Interventions: Drug: Maraviroc 300 mg
Behavioral: Rehabilitation therapy
Drug: Placebo 300 mg

First Posted Date: 2017-05-31

Last Posted Date: 2021-08-03

Lead Sponsor: University of California, Los Angeles

Target Recruit Count: 2

Registration Number: NCT03172026

Locations: 🇺🇸
California Rehabilitation Institute, Los Angeles, California, United States
🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸
Burke Neurological Research Institute, White Plains, New York, United States

Using Less Neurotoxic Drugs in Patients With HAND (MARAND-X)

Phase 4

Terminated

Conditions: Hiv
Neurocognitive Dysfunction

Interventions: Drug: emtricitabine, darunavir/cobicistat, maraviroc

First Posted Date: 2017-05-23

Last Posted Date: 2020-11-06

Lead Sponsor: Giovanni Di Perri

Target Recruit Count: 38

Registration Number: NCT03163277

Locations: 🇮🇹
University of Torino, Torino, Italy

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy